Rizza, PhD, Carroll L. Estes, PhD, Marie A. Bernard, MD, Marilyn R. Gugliucci, PhD, Suzanne R. Kunkel, PhD, and Harvey L. Sterns, PhD. Closing Plenary Program: Sunday, March 7, 9 a.m. ‘Curiosity Must Be Kept Alive’: Eleanor Roosevelt, Her OLD AGE: 1945-1962 The well-known first lady will recall the issues, losses, and adventures of her old age – dealing with loneliness after Franklin’s loss of life, coming into her own as a U.N. Delegate and seat of the Human Rights Commission, and learning to face the knowledge of aging with humor and honesty. This living history portrait is conducted by celebrity Elena Dodd.Mel, M.D., Ph.D., Blanca Munarriz, M.D., Ph.D., Cristina Llorca, M.D., Ph.D., Carlos Jara, M.D., Ph.D., Emilio Alba, M.D., Ph.D.D., Junfang Li, Ph.D.D.D.D., Sergio Almenar, M.D.D., and Ana Lluch, M.D., Ph.D. For the GEICAM 9805 Investigators: Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer The survival great things about adjuvant chemotherapy for individuals with early-stage breast cancers are well established. The 15-season survival outcomes from the first Breast Malignancy Trialists’ Collaborative Group 1 showed a combined chemotherapy program of cyclophosphamide, methotrexate, and fluorouracil reduces annual recurrence and death rates, a benefit that is mainly independent of tamoxifen use or nonuse, estrogen-receptor status, nodal status, and other tumor features.1 This meta-analysis also showed that anthracycline-based regimens give yet another advantage over CMF.